viewZelira Therapeutics Ltd

Zelira Therapeutics in trading halt ahead of insomnia trial results

The insomnia trial is designed to evaluate the safety and efficacy of a THC and CBD cannabinoid extract.

Zelira Therapeutics Ltd. - Zelira Therapeutics in trading halt ahead of insomnia trial results
Shares last traded 5.8 cents before being halted

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has been granted a trading halt pending the release of interim results of its insomnia clinical trial.

Shares will remain halted until the earlier of either the release of relevant information or the commencement of trading on Wednesday 19 February 2020.

Trial treating 24 patients in Perth

The Zelira insomnia trial was designed to evaluate the safety and efficacy of a cannabinoid extract containing THC and CBD in patients with symptoms of clinically diagnosed chronic insomnia.

This trial is the first in the world to have a primary endpoint assessing the impact of a full-spectrum cannabis extract on sleep.

A randomised, double-blinded, placebo-controlled, cross over study design was used to treat 24 patients with Zelira’s proprietary insomnia formulation and a placebo formulation delivered sublingually.

Insomnia is a multibillion-dollar market

An estimated 70 million Americans have insomnia where the market for prescription and over-the-counter medications used to treat the condition generates over US$2 billion in annual revenue.

Quick facts: Zelira Therapeutics Ltd

Price: 0.053 AUD

Market: ASX
Market Cap: $51.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read